The 26.6 Data Release includes updates to human studies including FunGen-AD and Diverse Cohorts; and animal model studies including the MARMO-AD and PAK1 Inhibitor 5xFAD studies.

Proper acknowledgment of data sources is not only mandatory for users of the AD Knowledge Portal, it also enhances the visibility of your work and elevates recognition of datasets used. All data use must be acknowledged with the following: the AD Knowledge Portal Acknowledgement Statement; and an Acknowledgement Statement specific to the study/dataset used, from the relevant Study page; and a Data Availability statement that includes a direct link to access relevant resources, known as a dataset DOI. For more information and pre-written acknowledgement statements, see Data Use & Acknowledgement.

Human

  • The FunGen-AD Study

    This study investigates the biological role of circPDE4B, a highly abundant circular RNA that is markedly downregulated in Alzheimer’s disease across brain regions, using sequencing-derived expression and non-coding RNA profiling data from human neuronal progenitor cell experiments.

    • This release includes RIP-smRNA-seq data from circPDE4B immunoprecipitation and scrambled control samples to support identification of potential miRNA partners, and functional and sequencing-based analyses suggest that circPDE4B regulates translational stress, GEMIN5-associated RNA regulation, autophagy, and other post-transcriptional pathways relevant to neuronal homeostasis and AD pathophysiology.

  • The AMP-AD_Diverse Cohorts Study

    The AMP-AD Diverse Cohorts Study is a cross-consortium project generating harmonized datasets from diverse human cohorts. This study provides post-mortem multi-omic data from over 850 individuals, including 305 Black or African American individuals and 336 Hispanic or Latino individuals representing the spectrum of Alzheimer’s Disease phenotypes. Samples were provided by Rush University, Emory University, the Mayo Clinic, Columbia University, and Mt Sinai Medical School.

    • This release from the AMP-AD Diverse Cohorts studies includes recurated metabolomics data identifying additional metabolites from 780 samples

  • The MSBB and ROSMAP Cohort AD Resilience Study

    The MSBB and ROSMAP Cohort AD Resilience Study is a multi-omics resource containing matched transcriptomic (170 bulk RNA-seq) and proteomic (282 TMT-based) profiles from postmortem prefrontal cortex (PFC) tissue of neurologically normal individuals. The samples were contributed by the Mount Sinai Brain Bank (MSBB) and the Religious Orders Study and Memory and Aging Project (ROSMAP). Participants are categorized as young-old (YO; 60–84 years) or oldest-old (OO; ≥85 years) to study age-associated molecular signatures and AD resilience. Matched whole-genome sequencing (WGS) data are also available for most subjects, facilitating integrated multi-omics and systems-level analyses.

    • The release contains raw RNA-seq and processed proteomics files.

  • The SEA-AD Study

    This study provides transcriptomic and chromatin accessibility data from single nuclei isolated from multiple brain tissues of 84 aged individuals spanning the full spectrum of Alzheimer’s disease severity and 5 neurotypical adult reference individuals. The Seattle Alzheimer’s Disease Brain Cell Atlas (SEA-AD) consortium includes the Allen Institute for Brain Science, the University of Washington, and Kaiser Permanente Washington Health Research Institute.

    • This release provides versioning updates to the metadata, including updates to the specimenIDs, and corrections to file annotations.

Models

  • The TREAT-AD – PAK1 Inhibitor 5xFAD Study

    This is a study of a familial Alzheimer’s disease mouse model expressing mutant human APP and PSEN1. 5XFAD transgenic mice overexpress both mutant human APP with the Swedish (K670N, M671L), Florida (I716V), and London (V717I) Familial Alzheimers Disease (FAD) mutations and mutant human PSEN1 with two FAD mutations (M146L and L286V). Expression of both transgenes is regulated by neural-specific elements of the mouse Thy1 promoter to drive overexpression in the brain. The 5XFAD transgenic mice rapidly recapitulate major features of Alzheimer’s disease amyloid pathology and may be useful models of intraneuronal Aβ-42 induced neurodegeneration and amyloid plaque formation.

    • This release provides data from 5XFAD mice dosed with a selective PAK1 inhibitor (NVS-PAK1-1), conducted by the Emory/Sage/SGC/JAX TREAT-AD Center.

  • The MARMO-AD Study

    The MARMO-AD Study aims to generate, characterize, and validate the marmoset as a non-human primate model of aging and Alzheimer’s Disease.

    • This study aims to generate, characterize, and validate the marmoset as a non-human primate model of aging and Alzheimer’s Disease. This release includes updates to metadata files.

  • The UCI_ABI3 Study

    The Alzheimer’s Disease (AD)-associated ABI3S209F (Abi3S212F in mouse) variant regulates cytoskeletal dynamics, but its in vivo impact on pathology is unknown. This study characterizes the effects of Abi3S212F on two different AD mouse models: 5xFAD hemizygous (develops amyloid plaques) and hAβ-KI homozygous (does not develop amyloid plaques). This initial release includes bulk RNA-seq, immunohistochemistry, biochemistry, and plasma neurofilament light chain (NfL) data from male and female mice of each cohort. 4-, 12-, and 18-month data are available for all experiments; 24-month data are available for specific experiments, as shown in the methods descriptions. The Alzheimer’s Disease (AD)-associated ABI3S209F (Abi3S212F in mouse) variant regulates cytoskeletal dynamics, but its in vivo impact on pathology is unknown. This study characterizes the effects of Abi3S212F on two different AD mouse models: 5xFAD hemizygous (develops amyloid plaques) and hAβ-KI homozygous (does not develop amyloid plaques). 

    • This initial release includes bulk RNA-seq, immunohistochemistry, biochemistry, and plasma neurofilament light chain (NfL) data from male and female mice of each cohort. 4-, 12-, and 18-month data are available for all experiments; 24-month data are available for specific experiments, as shown in the methods descriptions.